Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 23

1.

The role of dimethylarginine dimethylaminohydrolase (DDAH) in pulmonary fibrosis.

Janssen W, Pullamsetti SS, Cooke J, Weissmann N, Guenther A, Schermuly RT.

J Pathol. 2013 Jan;229(2):242-9. doi: 10.1002/path.4127. Review.

PMID:
23097221
2.

Dimethylarginine dimethylaminohydrolase regulation: a novel therapeutic target in cardiovascular disease.

Wadham C, Mangoni AA.

Expert Opin Drug Metab Toxicol. 2009 Mar;5(3):303-19. doi: 10.1517/17425250902785172 . Review.

PMID:
19331593
3.

The DDAH/ADMA/NOS pathway.

Tran CT, Leiper JM, Vallance P.

Atheroscler Suppl. 2003 Dec;4(4):33-40. Review.

PMID:
14664901
4.

Inhibitors of the Hydrolytic Enzyme Dimethylarginine Dimethylaminohydrolase (DDAH): Discovery, Synthesis and Development.

Murphy RB, Tommasi S, Lewis BC, Mangoni AA.

Molecules. 2016 May 11;21(5). pii: E615. doi: 10.3390/molecules21050615. Review.

5.

The prominent role of the liver in the elimination of asymmetric dimethylarginine (ADMA) and the consequences of impaired hepatic function.

Richir MC, Bouwman RH, Teerlink T, Siroen MP, de Vries TP, van Leeuwen PA.

JPEN J Parenter Enteral Nutr. 2008 Nov-Dec;32(6):613-21. doi: 10.1177/0148607108321702. Review.

PMID:
18974239
6.

The therapeutic potential of targeting endogenous inhibitors of nitric oxide synthesis.

Leiper J, Nandi M.

Nat Rev Drug Discov. 2011 Apr;10(4):277-91. doi: 10.1038/nrd3358. Review.

PMID:
21455237
7.

Dimethylarginine dimethylaminohydrolase (DDAH): expression, regulation, and function in the cardiovascular and renal systems.

Palm F, Onozato ML, Luo Z, Wilcox CS.

Am J Physiol Heart Circ Physiol. 2007 Dec;293(6):H3227-45. Epub 2007 Oct 12. Review.

8.

The role of asymmetric dimethylarginine and arginine in the failing heart and its vasculature.

Visser M, Paulus WJ, Vermeulen MA, Richir MC, Davids M, Wisselink W, de Mol BA, van Leeuwen PA.

Eur J Heart Fail. 2010 Dec;12(12):1274-81. doi: 10.1093/eurjhf/hfq158. Epub 2010 Oct 5. Review.

9.

Role of asymmetric dimethylarginine (ADMA) in diabetic vascular complications.

Yamagishi S, Ueda S, Nakamura K, Matsui T, Okuda S.

Curr Pharm Des. 2008;14(25):2613-8. Review.

PMID:
18991678
10.

The endothelial ADMA/NO pathway in hypoxia-related chronic respiratory diseases.

Lüneburg N, Harbaum L, Hennigs JK.

Biomed Res Int. 2014;2014:501612. doi: 10.1155/2014/501612. Epub 2014 Feb 25. Review.

12.

Role of the PRMT-DDAH-ADMA axis in the regulation of endothelial nitric oxide production.

Pope AJ, Karuppiah K, Cardounel AJ.

Pharmacol Res. 2009 Dec;60(6):461-5. doi: 10.1016/j.phrs.2009.07.016. Epub 2009 Aug 12. Review.

13.

The biology and therapeutic potential of the DDAH/ADMA pathway.

Arrigoni F, Ahmetaj B, Leiper J.

Curr Pharm Des. 2010;16(37):4089-102. Review.

PMID:
21247398
14.

Liver plays a central role in asymmetric dimethylarginine-mediated organ injury.

Ferrigno A, Di Pasqua LG, Berardo C, Richelmi P, Vairetti M.

World J Gastroenterol. 2015 May 7;21(17):5131-7. doi: 10.3748/wjg.v21.i17.5131. Review.

15.

Matrix metalloproteinases as therapeutic targets for idiopathic pulmonary fibrosis.

Craig VJ, Zhang L, Hagood JS, Owen CA.

Am J Respir Cell Mol Biol. 2015 Nov;53(5):585-600. doi: 10.1165/rcmb.2015-0020TR. Review.

16.
17.

The emerging role of asymmetric dimethylarginine as a novel cardiovascular risk factor.

Böger RH.

Cardiovasc Res. 2003 Oct 1;59(4):824-33. Review.

PMID:
14553822
18.

Role of matrix metalloproteinases in the pathogenesis of idiopathic pulmonary fibrosis.

Pardo A, Cabrera S, Maldonado M, Selman M.

Respir Res. 2016 Mar 4;17:23. doi: 10.1186/s12931-016-0343-6. Review.

19.

Modulating DDAH/NOS Pathway to Discover Vasoprotective Insulin Sensitizers.

Lai L, Ghebremariam YT.

J Diabetes Res. 2016;2016:1982096. doi: 10.1155/2016/1982096. Epub 2015 Dec 6. Review.

20.

The Rho kinases: critical mediators of multiple profibrotic processes and rational targets for new therapies for pulmonary fibrosis.

Knipe RS, Tager AM, Liao JK.

Pharmacol Rev. 2015;67(1):103-17. doi: 10.1124/pr.114.009381. Review.

Supplemental Content

Support Center